News

Successful Exit Versantis

We are proud and congratulate our portfolio company Versantis on its exit. French buyer GENFIT, a late-stage biopharmaceutical company, aims to strengthen its position as a leader in acute-on-chronic liver failure (ACLF) through Versantis’ strong pipeline of a Phase 2 ready program based on first-in-class scavenging liposomes technology, a pediatric program focused on urea cycle disorder (UCD), and an early-stage program focused on hepatic encephalopathy (HE).

GENFIT pays CHF 40 million upfront and an additional CHF 65 million contingent on successful clinical and regulatory milestones, as well as one-third of the net proceeds from the potential sale of a priority review voucher, if awarded by the FDA.

More information in the press release under the following Link.

Initial investment in Avelo Overview adivo achieves two major milestones
Want to learn more about OCCIDENT?

News

About

New OCCIDENT Website

Having sharpened our investor profile and revised our communi­cation, we get to the point: OCCIDENT – The Science Investor.